PUBLISHER: The Business Research Company | PRODUCT CODE: 1681953
PUBLISHER: The Business Research Company | PRODUCT CODE: 1681953
Biologic imaging reagents encompass substances or compounds employed in diverse imaging techniques to augment the visibility and contrast of biological structures, molecules, or processes. These reagents are specifically designed to interact with distinct biological targets, such as proteins, nucleic acids, or cellular structures, thereby enhancing their visibility and distinguishability during imaging.
The primary categories of products within biologic imaging reagents include contrast reagents, optical imaging reagents, and radiopharmaceuticals. Contrast reagents are substances utilized in medical imaging to amplify the visibility of specific tissues. This encompasses various modalities such as magnetic resonance imaging (MRI), ultrasound, x-ray, and computerized tomography (CT), nuclear, optical, and others, applied in various contexts, including in vitro and in vivo. Diagnostic laboratories, imaging centers, life science companies, research and academic institutes, and other entities make use of these reagents.
The biologic imaging reagents market research report is one of a series of new reports from The Business Research Company that provides biologic imaging reagents market statistics, including biologic imaging reagents industry global market size, regional shares, competitors with a biologic imaging reagents market share, detailed biologic imaging reagents market segments, market trends and opportunities, and any further data you may need to thrive in the biologic imaging reagents industry. This biologic imaging reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The biologic imaging reagents market size has grown rapidly in recent years. It will grow from $18.41 billion in 2024 to $20.26 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to rise in prevalence of chronic diseases, growing research and development investments, shift towards personalized medicine, focus on early disease detection, increasing geriatric population, collaborations in biomedical research.
The biologic imaging reagents market size is expected to see strong growth in the next few years. It will grow to $27.78 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to expanding applications in drug development, rising demand for molecular imaging, focus on non-invasive diagnostic methods, global increase in cancer cases, shift towards value-based healthcare. Major trends in the forecast period include rise in demand for contrast-enhanced imaging agents, development of targeted molecular imaging agents, application of nanoparticles in imaging, emergence of fluorescent probes for in vivo imaging, integration of artificial intelligence in image analysis.
The rising prevalence of chronic diseases is anticipated to drive the growth of the biologic imaging reagents market in the future. Chronic diseases are defined as conditions lasting one year or longer that require ongoing medical care and may deteriorate over time. These diseases necessitate the use of biologic imaging reagents to diagnose and identify issues by visualizing organs and affected structures. For example, in 2022, the American Cancer Society, a US-based voluntary organization, estimated that there would be 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. Additionally, in January 2023, the National Library of Medicine, a US-based agency, reported that the number of individuals aged 50 and older in the US with at least one chronic condition is expected to increase by 99.5%, rising from 71.522 million to 142.66 million by 2050. Thus, the growing prevalence of chronic diseases is fueling the expansion of the biologic imaging reagents market.
The increasing demand for personalized medicine is anticipated to contribute to the growth of the biologic imaging reagents market. Personalized medicine tailors healthcare decisions and treatments to individual patient characteristics, utilizing biologic imaging reagents to visualize biological processes at the molecular and cellular level. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research approved 37 new molecular entities, with approximately 34% (12) classified as personalized medicines by the Personalized Medicine Coalition. This growing demand for personalized medicine is a significant factor driving the biologic imaging reagents market.
Major players in the biologic imaging reagents market are dedicating their efforts to the development of innovative reagents, particularly novel dye technology, providing a new tool for researchers and clinicians to enhance the sensitivity and specificity of biologic imaging. Novel dye technology involves the creation of new dyes for various applications, including biological imaging. In April 2022, Becton, Dickinson, and Company, a US-based medical device company, introduced BD Horizon RealYellow 586 Reagents and RealBlue Reagents. This new line of reagents enables researchers to obtain higher data resolution and more insights from samples compared to standard fluorochrome. The improvement is attributed to the incorporation of revolutionary dye technology and artificial intelligence (AI) supervision. The AI analyzed existing data from excitation and emission profiles of commercially available fluorochromes, determining optimal positions in laser lines for the development of novel dyes.
In October 2024, Bracco S.p.A, an Italy-based healthcare company specializing in biological imaging reagents, entered into a partnership with Subtle Medical. This collaboration aims to combine Bracco's expertise in contrast imaging with deep-learning technology to redefine diagnostic precision and efficiency in medical imaging. Additionally, Bracco S.p.A received approval from the Food and Drug Administration (FDA), a US federal agency, for its AI-powered software, AiMIFY, which is classified as Class II software as a medical device (SaMD) specifically designed to enhance magnetic resonance imaging (MRI) of the brain. Subtle Medical is a US-based healthcare technology company.
Major companies operating in the biologic imaging reagents market report are Cardinal Health Inc., Johnson And Johnson Services Inc., Bayer Healthcare AG, Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Dickinson and Company (BD), Koninklijke Philips N.V., GE HealthCare Technologies Inc., Stryker Corporation, FluoroPharma Medical Inc., Lonza Group AG, Illumina Inc., PerkinElmer Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Bracco Diagnostics Inc., Leica Microsystems GmbH, Lantheus Medical Imaging Inc., Guerbet SA, Miltenyi Biotec B.V. and Co. KG, Promega Corporation, Abcam plc., Luminex Corporation, MILabs, LI-COR Biosciences, FUJIFILM VisualSonics Inc., Advanced Proteome Therapeutics Incorporated, BIOPRO Baden-Wurttemberg GmbH, ABX Advanced Biochemical Compounds GmbH
North America was the largest region in the biologic imaging reagents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologic imaging reagents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the biologic imaging reagents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The biologic imaging reagents market consists of sales of gadolinium-based contrast agents, iodinated contrast agents, microbubbles, nanoparticles, bioluminescent probes, immunohistochemistry reagents, optical imaging agents, paramagnetic agents and fluorescent dyes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biologic Imaging Reagents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on biologic imaging reagents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for biologic imaging reagents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologic imaging reagents market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.